Guardant Health, Inc. (GH)

Market Cap	2.11B
Revenue (ttm)	563.95M
Net Income (ttm)	-479.45M
Shares Out	121.71M
EPS (ttm)	-4.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	682,749
Open	16.98
Previous Close	17.16
Day's Range	16.77 - 17.52
52-Week Range	15.81 - 41.06
Beta	0.90
Analysts	Buy
Price Target	39.20 (+125.94%)
Earnings Date	May 9, 2024

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for adv...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 1,779
• Stock Exchange: NASDAQ
• Ticker Symbol: GH

Financial Performance

In 2023, GH's revenue was $563.95 million, an increase of 25.45% compared to the previous year's $449.54 million. Losses were -$479.45 million, -26.76% less than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for GH stock is "Buy." The 12-month stock price forecast is $39.2, which is an increase of 125.94% from the latest price.

Price Target

$39.2

(125.94% upside)

Analyst Consensus: Buy